STAGING PREVIEW. Actives and declared doses are real; batch number, assay values and lab results are placeholder.
Peak PeptidesAustralia
Certificate of Analysis
Batch LI-2608-173
Issued 14 July 2026
99.7%Purity, HPLC
1Declared active
9Parameters tested
17025ISO/IEC accredited
Product identification
Product name
Peak Libido™ — 30-day pen
Presentation
Lyophilised powder, multi-dose pen cartridge
Batch / lot number
LI-2608-173
Manufacture date
2026-06-28
Retest date
2028-06-28
Storage
2–8 °C after reconstitution · protect from light
Composition — declared vs assayed
Active
Declared / pen
Assayed
Result
HCG
20,000iu
20,000iu
Pass
Analytical results
Test
Method
Specification
Result
Appearance
Visual
White lyophilised cake
Conforms Pass
Purity
RP-HPLC, 214 nm
≥ 98.0 %
99.7 % Pass
Identity
ESI-MS
Conforms to theoretical
Conforms Pass
Water content
Karl Fischer
≤ 8.0 %
3.1 % Pass
Bacterial endotoxin
LAL kinetic
< 0.20 EU/mg
< 0.05 EU/mg Pass
Residual TFA
Ion chromatography
≤ 1.0 %
0.28 % Pass
Heavy metals
ICP-MS
Within limits
Conforms Pass
Microbial limits
Plate count
< 100 CFU/g
< 10 CFU/g Pass
Chromatogram — RP-HPLC, 214 nm
Method summary
Column
C18, 4.6 × 250 mm, 5 µm
Mobile phase A
0.1 % TFA in water
Mobile phase B
0.1 % TFA in acetonitrile
Gradient
5 → 65 % B over 20 min
Detection
UV 214 nm
A. Whitfield
Analytical Chemist Released 14 July 2026
M. Kaur
Quality Assurance Manager Approved 14 July 2026
Testing performed by an independent ISO/IEC 17025-accredited laboratory.
This certificate relates only to the batch identified above. Staging preview — placeholder lab data.